RP3

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611Replimune, Inc.Phase 2Terminated2025-08-18Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.